// App-Quantinova.ai

261 : Secukinumab 150 mg provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 4-year results from the Phase 3 trial, MEASURE 2

Researchers

Presenter

  • Helena Marzo-Ortega

Principal Investigators

  • Joachim Sieper

  • Alan Kivitz

  • Richardo Blanco

  • Martin Cohen

  • Eumorphia-Maria Delicha

  • Susanne Rohrer

  • Hanno Richards

Medical Centers

  • NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, University of Leeds, Leeds, UNITED KINGDOM

  • Department of Gastroenterology, Infection and Rheumatology, University Clinic Benjamin Franklin, Berlin, GERMANY

  • Altoona Center for Clinical Research, Duncansville, PA

  • Hematology, Hospital Universitario Marques de Valdecilla, Santander, Spain

  • Pediatric Radiology, McGill University, Montreal, QC, Canada

  • Immunology, Hepatology, and Dermatology Development Unit, Novartis Pharma AG, Basel, SWITZERLAND

Locations

  • United Kingdom

  • Germany

  • United States

  • Spain

  • Canada

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Autoimmune (AI)

Disease

  • Ankylosing spondylitis

Biomarkers

  • N/A

Drug/Treatment

  • secukinumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • NCT01649375

Sponsors

  • Celgene and Janssen

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved